Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Sztiller Sikorska, Malgorzata ^a   Koprowska, Kamila ^a   Majchrzak, Kinga ^a   Hartman, Mariusz ^a   Czyz, Malgorzata ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

4 IPOMEANOL; ABC TRANSPORTER B5; ALANTOLACTONE; BRYOSTATIN 1; CASTANOSPERMINE; COLCHICINE; CROTON FACTOR F1; CYTOTOXIC AGENT; ECHINOMYCIN; ECHINOMYCIN A; FUMAGALLIN; FUMITREMORGIN C; ILLUDIN M; MAYTANSINE; MICHELLAMINE B; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; MYC PROTEIN; NANAOMYCIN A; NATURAL PRODUCT; NORDRACORUBIN; PARTHENIN; PENTOXIFYLLINE; ROTENONE; RUFOCROMOMYCIN; SIOMYCIN A; TENIPOSIDE; TOYOCAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALINOMYCIN; WORTMANNIN;

ANCHORAGE INDEPENDENT GROWTH; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER STEM CELL; CELL CYCLE ARREST; CELL LABELING; CELL POPULATION; CELL RENEWAL; CELL SUBPOPULATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; DRUG STRUCTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MELANOCYTE; MELANOMA; MELANOMA CELL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; STRUCTURE ANALYSIS;

APOPTOSIS; BIOLOGICAL PRODUCTS; CELL CYCLE CHECKPOINTS; CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; DRUG DISCOVERY; GENE EXPRESSION REGULATION; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; NAPHTHOQUINONES; NEOPLASTIC STEM CELLS; STREPTONIGRIN; TOYOCAMYCIN;

EID: 84896929154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090783     Document Type: Article

References (80)

1. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65: 9328-9337. (Pubitemid 41508000)
2. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, et al. (2008) Identification of cells initiating human melanomas. Nature 451: 345-349.
3. Hermann PC, Bhaskar S, Cioffi M, Heeschen C (2010) Cancer stem cells in solid tumors. Semin Cancer Biol 20: 77-84.
4. Quintana E, Shackleton M, Foster HR, Fullen DR, Sabel MS, et al. (2010) Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18: 510-523.
5. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, et al. (2010) A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 141: 583-594.
6. Hoek KS, Goding CR (2010) Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 23: 746-759.
7. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, et al. (2012) Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene 31: 4898-4911.
8. Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17: 313-319.
9. Rosen JM, Jordan CT (2009) The increasing complexity of the cancer stem cell paradigm. Science 324: 1670-1673.
10. He K, Xu T, Goldkorn A (2011) Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther 10: 938-948.
11. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, et al. (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 108: 7950-7955.
12. Bragado P, Estrada Y, Sosa MS, Avivar-Valderas A, Cannan D, et al. (2012) Analysis of marker-defined HNSCC subpopulations reveals a dynamic regulation of tumor initiating properties. PLoS ONE 7: e29974.
13. Akunuru S, Zhai QJ, Zheng Y (2012) Non-small cell lung cancer stem/progenitor cells are enriched in multiple distinct phenotypic subpopulations and exhibit plasticity. Cell Death Dis 3: e352.
14. Gomez-Cabrero A, Wrasidlo W, Reisfeld RA (2013) IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model. PLoS ONE 8: e73607.
15. Sztiller-Sikorska M, Koprowska K, Jakubowska J, Zalesna I, Stasiak M, et al. (2012) Sphere formation and self-renewal capacity of melanoma cells is affected by the microenvironment. Melanoma Res 22: 215-224.
16. Perego M, Tortoreto M, Tragni G, Mariani L, Deho P, et al. (2010) Heterogeneous phenotype of human melanoma cells with in vitro and in vivo features of tumor-initiating cells. J Invest Dermatol 130: 1877-1886.
17. Ramgolam K, Lauriol J, Lalou C, Lauden L, Michel L, et al. (2011) Melanoma spheroids grown under neural crest cell conditions are highly plastic migratory/invasive tumor cells endowed with immunomodulator function. PLoS ONE 6: e18784.
18. Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, et al. (2011) Inverse expression states of the BRN2 and MITF transcription factors in melanoma spheres and tumour xenografts regulate the NOTCH pathway. Oncogene 30(27): 3036-3048.
19. Gu J, Gui Y, Chen L, Yuan G, Lu H-Z, et al. (2013) Use of natural products as chemical library for drug discovery and network pharmacology. PLoS ONE 8: e62839.
20. Clardy J, Walsh C (2004) Lessons from natural molecules. Nature 432: 829-837. (Pubitemid 40037138)
21. D'Incalci M, Brunelli D, Marangon E, Simone M, Tavecchio M, et al. (2007) Modulation of gene transcription by natural products - a viable anticancer strategy. Curr Pharm Des 13: 2744-2750. (Pubitemid 350138965)
22. Chartrain M, Riond J, Stennevin A, Vandenberghe I, Gomes B, et al. (2012) Melanoma chemotherapy leads to the selection of ABCB5-expressing cells. PLoS ONE 7: e36762.
23. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, et al. (2005) ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 65: 4320-4333. (Pubitemid 40775671)
24. Elliott AM, Al-Hajj MA (2009) ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res 7: 79-87.
25. Valkenburg KC, Graveel CR, Zylstra-Diegel CR, Zhong Z, Williams BO (2011) Wnt/beta-catenin signaling in normal and cancer stem cells. Cancers 3: 2050-2079.
26. Hallett RM, Kondratyev MK, Giacomelli AO, Nixon AML, Girgis-Gabardo A, et al. (2012) Small molecule antagonists of the Wnt/beta-catenin signaling pathway target breast tumor-initiating cells in a Her2/Neu mouse model of breast cancer. PLoS ONE 7: e33976.
27. Sinnberg T, Menzel M, Ewerth D, Sauer B, Schwarz M, et al. (2011) b-catenin signaling increases during melanoma progression and promotes tumor cell survival and chemoresistance. PLoS ONE 6: e23429.
28. Goding CR (2011) Commentary. A picture of Mitf in melanoma immortality. Oncogene 30: 2304-2306.
29. Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, et al. (2005) Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436: 117-122. (Pubitemid 40966196)
30. Haq R, Yokoyama S, Hawryluk EB, Jonsson GB, Frederick DT, et al. (2013) BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci USA 110: 4321-4326.
31. Dang CV (2012) MYC on the path to cancer. Cell 149: 22-35.
32. Helm F, Kammertoens T, Lehmann FM, Wilke A, Bruns H, et al. (2013) Targeting c-MYC with T-cells. PLoS ONE 8: e77375.
33. Frenzel A, Zirath H, Vita M, Albihn A, Henriksson MA (2011) Identification of cytotoxic drugs that selectively target tumor cells with MYC overexpression. PLoS ONE 6: e27988.
34. Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, et al. (2008) Modelling Myc inhibition as a cancer therapy. Nature 455: 679-683.
35. Mannava S, Grachtchouk V, Wheeler LJ, Im M, Zhuang D, et al. (2008) Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle 7: 2392-2400.
36. Czyz M, Koprowska K, Sztiller-Sikorska M (2013) Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres. Cancer Biol Ther 14: 135-145.
37. Koprowska K, Hartman ML, Sztiller-Sikorska M, Czyz ME (2013) Parthenolide enhances dacarbazine activity against melanoma cells. Anticancer Drugs 24: 835-845.
38. Bolzán AD, Bianchi MS (2001) Genotoxicity of streptonigrin: a review. Mutat Res 488: 25-37. (Pubitemid 32166781)
39. Gavriil M, Tsao CC, Mandiyan S, Arndt K, Abraham R, et al. (2009) Specific IKKbeta inhibitor IV blocks Streptonigrin-induced NF-kappaB activity and potentiates its cytotoxic effect on cancer cells. Mol Carcinog 48: 678-684.
40. Lewis AM, Ough M, Hinkhouse MM, Tsao MS, Oberley LW, et al. (2005) Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer. Mol Carcinog 43: 215-224. (Pubitemid 41134429)
41. Park S, Chun S (2011) Streptonigrin inhibits b-Catenin/Tcf signaling and shows cytotoxicity in b-catenin-activated cells. Biochim Biophys Acta 1810: 1340-1345.
42. Garate M, Wani AA, Li G (2010) The NAD(P)H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radic Biol Med 48: 1601-1609.
43. Zhao D, Amria S, Hossain A, Sundaram K, Komlosi P, et al. (2011) Enhancement of HLA class II-restricted CD4+ T cell recognition of human melanoma cells following treatment with bryostatin-1. Cell Immunol 271: 392-400.
44. Bhat UG, Zipfel PA, Tyler DS, Gartel AL (2008) Novel anticancer compounds induce apoptosis in melanoma cells. Cell Cycle 7: 1851-1855. (Pubitemid 351988751)
45. Nakano I, Joshi K, Visnyei K, Hu B, Watanabe M, et al. (2011) Siomycin A targets brain tumor stem cells partially through a MELK-mediated pathway. Neuro Oncol 13: 622-634.
46. Theron T, Binder A, Verheye-Dua F, Böhm L (2000) The role of G2-block abrogation, DNA double-strand break repair and apoptosis in the radiosensitization of melanoma and squamous cell carcinoma cell lines by pentoxifylline. Int J Radiat Biol 76: 1197-1208.
47. Dua P, Gude RP (2006) Antiproliferative and antiproteolytic activity of pentoxifylline in cultures of B16F10 melanoma cells. Cancer Chemother Pharmacol 58: 195-202.
48. Shukla V, Gude RP (2003) Potentiation of antimetastatic activity of pentoxifylline in B16F10 and B16F1 melanoma cells through inhibition of glutathione content. Cancer Biother Radiopharm 18: 559-564. (Pubitemid 37082375)
49. Jain M, Ratheesh A, Gude RP (2010) Pentoxifylline inhibits integrin-mediated adherence of 12(S)-HETE and TNFalpha-activated B16F10 cells to fibronectin and endothelial cells. Chemotherapy 56: 82-88.
50. Kamran MZ, Gude RP (2012) Preclinical evaluation of the antimetastatic efficacy of Pentoxifylline on A375 human melanoma cell line. Biomed Pharmacother 66: 617-626.
51. Kamran MZ, Gude RP (2013) Pentoxifylline inhibits melanoma tumor growth and angiogenesis by targeting STAT3 signaling pathway. Biomed Pharmacother 67: 399-405.
52. Suhadolnik RJ, Uematsu T, Uematsu H (1967) Toyocamycin: phosphorylation and incorporation into RNA and DNA and the biochemical properties of the triphosphate. Biochim Biophys Acta 149: 41-49.
53. Tavitian A, Uretsky SC, Acs G (1969) The effect of toyocamycin on cellular RNA synthesis. Biochim Biophys Acta 179: 50-57.
54. Kiburu IN, LaRonde-LeBlanc N (2012) Interaction of Rio1 kinase with toyocamycin reveals a conformational switch that controls oligomeric state and catalytic activity. PLoS ONE 7: e37371.
55. Ri M, Tashiro E, Oikawa D, Shinjo S, Tokuda M, et al. (2012) Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J 2: e79.
56. Kuck D, Caulfield T, Lyko F, Medina-Franco JL (2010) Nanaomycin A selectively inhibits DNMT3B and reactivates silenced tumor suppressor genes in human cancer cells. Mol Cancer Ther 9: 3015-3023.
57. Caulfield T, Medina-Franco JL (2011) Molecular dynamics simulations of human DNA methyltransferase 3B with selective inhibitor nanaomycin A. J Struct Biol 176: 185-191.
58. Zhai JM, Yin XY, Hou X, Hao XY, Cai JP, et al. (2013) Analysis of the genome-wide DNA methylation profile of side population cells in hepatocellular carcinoma. Dig Dis Sci 58: 1934-1947.
59. McMorris TC, Kelner MJ, Wang W, Moon S, Taetle R (1990) On the mechanism of toxicity of illudins: the role of glutathione. Chem Res Toxicol 3: 574-579.
60. Knauer S, Biersack B, Zoldakova M, Effenberger K, Milius W, et al. (2009) Melanoma-specific ferrocene esters of the fungal cytotoxin illudin M. Anticancer Drugs 20: 676-681.
61. Schobert R, Biersack B, Knauer S, Ocker M (2008) Conjugates of the fungal cytotoxin illudin M with improved tumour specificity. Bioorg Med Chem 16: 8592-8597.
62. Toyomura K, Saito T, Emori S, Matsumoto I, Kato E, et al. (2012) Effects of Hsp90 inhibitors, geldanamycin and its analog, on ceramide metabolism and cytotoxicity in PC12 cells. J Toxicol Sci 37: 1049-1057.
63. van der Kraan AG, Chai RC, Singh PP, Lang BJ, Xu J, et al. (2013) HSP90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors. Biochem J 451: 235-244.
64. Sáez-Ayala M, Montenegro MF, Sánchez-Del-Campo L, Fernández-Pérez MP, Chazarra S, et al. (2013) Directed phenotype switching as an effective antimelanoma strategy. Cancer Cell 24: 105-119.
65. Rabindran SK, Ross DD, Doyle LA, Yang W, Greenberger LM (2000) Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer 60: 47-50. (Pubitemid 30058728)
66. Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, et al. (2012) EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 11: 73.
67. Chen GJ, Weylie B, Hu C, Zhu J, Forough R (2007) FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470). J Cell Biochem 101: 1492-1504. (Pubitemid 47242778)
68. Kilarski WW, Petersson L, Fuchs PF, Zielinski MS, Gerwins P (2012) An in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels. Angiogenesis 15: 643-655.
69. Sheen IS, Jeng KS, Jeng WJ, Jeng CJ, Wang YC, et al. (2005) Fumagillin treatment of hepatocellular carcinoma in rats: an in vivo study of antiangiogenesis. World J Gastroenterol 11: 771-777.
70. Sawanyawisuth K, Wongkham C, Pairojkul C, Saeseow OT, Riggins GJ, et al. (2007) Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target. Acta Oncol 46: 378-385. (Pubitemid 46625045)
71. Blum RH, Wittenberg BK, Canellos GP, Mayer RJ, Skarin AT, et al. (1978) A therapeutic trial of maytansine. Cancer Clin Trials 1: 113-117.
72. Borden EC, Ash A, Enterline HT, Rosenbaum C, Laucius JF, et al. (1982) Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas. Am J Clin Oncol 5: 417-420. (Pubitemid 12064503)
73. Cassady JM, Chan KK, Floss HG, Leistner E (2004) Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo) 52: 1-26. (Pubitemid 41685545)
74. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, et al. (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29: 398-405.
75. Blanc V, Bousseau A, Caron A, Carrez C, Lutz RJ, et al. (2011) SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies. Clin Cancer Res 17: 6448-6458.
76. Skoufias DA, Wilson L (1992) Mechanism of inhibition of microtubule polymerization by colchicine: inhibitory potencies of unliganded colchicine and tubulin-colchicine complexes. Biochemistry 31: 738-746.
77. Lin ZY, Wu CC, Chuang YH, Chuang WL (2013) Anti-cancer mechanisms of clinically acceptable colchicine concentrations on hepatocellular carcinoma. Life Sci 93: 323-328.
78. Chen XM, Liu J, Wang T, Shang J (2012) Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro 26: 649-655.
79. Leder K, Holland EC, Michor F (2010) The therapeutic implications of plasticity of the cancer stem cell phenotype. PLoS ONE 5: e14366.
80. Murphy GF, Wilson BJ, Girouard SD, Frank NY, Frank MH (2013) Stem cells and targeted approaches to melanoma cure. Mol Aspects Med, In Press. doi:10.1016/j.mam.2013.10.003.